Clementia Announces Pricing of Public Offering of Common Shares
29 Octubre 2018 - 7:21PM
Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a
clinical-stage biopharmaceutical company innovating treatments for
people with ultra-rare bone disorders and other diseases, today
announced the pricing of an underwritten public offering of
5,300,000 common shares at the price of $13.25 per share before
underwriting discounts and commissions. The gross proceeds to
Clementia from the offering, before deducting the underwriting
discounts and commissions and other offering expenses payable by
Clementia, are expected to be $70.2 million. The offering is
expected to close on November 1, 2018, subject to customary closing
conditions. In addition, Clementia has granted the underwriters a
30-day option to purchase up to an additional 795,000 common shares
from it at the public offering price, less underwriting discounts
and commissions.
Morgan Stanley and Leerink Partners are acting as book-running
managers for the offering. Wedbush PacGrow is acting as the
co-manager for the offering.
The securities described above are being offered by Clementia
pursuant to a shelf registration statement on Form F-3 that was
filed with the Securities and Exchange Commission (the "SEC") on
October 5, 2018, which was declared effective by the SEC on October
18, 2018. A preliminary prospectus supplement relating to and
describing the terms of the offering was filed with the SEC and is
available on the SEC's website at www.sec.gov. Copies of the final
prospectus supplement and the accompanying prospectus relating to
this offering, when available, may be obtained from: Morgan Stanley
at Attention: Prospectus Department, 180 Varick Street, 2nd Floor,
New York, New York 10014; or Leerink Partners LLC at Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA,
02110, or by telephone at (800) 808-7525, ext. 6132, or by email at
syndicate@leerink.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the applicable securities laws of any such
state or jurisdiction.
About Clementia Pharmaceuticals Inc.Clementia
is a clinical-stage company innovating treatments for people with
ultra-rare bone disorders and other diseases with high medical
need. The Company is preparing for a 2019 NDA submission to the FDA
to seek approval of its lead product candidate, palovarotene, a
novel RARγ agonist, for the treatment of fibrodysplasia ossificans
progressiva (FOP). The ongoing Phase 3 MOVE Trial is evaluating an
additional dosing regimen of palovarotene which includes a chronic
5 mg daily dose in addition to the episodic 20/10 mg dosing regimen
at the time of a flare-up. Palovarotene is also in a Phase 2 trial,
the MO-Ped Trial, for the treatment of multiple osteochondromas
(MO, also known as multiple hereditary exostoses, or MHE). In
addition, Clementia has commenced a Phase 1 trial for an eye drop
formulation of palovarotene for the potential treatment of dry eye
disease and is also investigating other conditions that may benefit
from RARγ therapy.
Cautionary Note Regarding Forward-Looking
StatementsThis press release may include “forward-looking
statements” within the meaning of the applicable securities laws,
including with respect to the proposed timing of submission of the
NDA for palovarotene. Each forward-looking statement contained in
this press release is subject to known and unknown risks and
uncertainties and other unknown factors that could cause actual
results to differ materially from historical results and those
expressed or implied by such statement. In addition to statements
which explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms “believes,”
“belief,” “expects,” “intends,” “anticipates,” “will,” or “plans”
to be uncertain and forward-looking. Applicable risks and
uncertainties include, among others, the Company’s ability to
successfully complete in a timely manner the studies required to be
completed in order to submit the NDA, the Company’s ability to
generate revenue and become profitable; the risks related to its
heavy reliance on palovarotene, its only current product candidate;
the risks associated with the development of palovarotene and any
future product candidate, including the demonstration of efficacy
and safety; its dependence on licensed intellectual property,
including the ability to source and maintain licenses from
third-party owners; as well as the risks identified under the
heading “Risk Factors” in the Company’s Annual Report on Form 20-F
filed with the Securities and Exchange Commission (“SEC”), as well
as the other information it files with the SEC or on SEDAR.
Clementia cautions investors not to rely on the forward-looking
statements contained in this press release when making an
investment decision in its securities. Investors are encouraged to
read the Company’s filings with the SEC or on SEDAR, available at
www.sec.gov or www.sedar.com, for a discussion of these and other
risks and uncertainties. The forward-looking statements in this
press release speak only as of the date of this press release, and
the Company undertakes no obligation to update or revise any of
these statements, whether as a result of new information, future
events or otherwise, except as required by law.
Investor/Media Contacts:Joseph
WalewiczClementia Pharmaceuticals Inc.+1-514-940-1080
Alicia DavisTHRUST Strategic
Communications+1-910-620-3302alicia@thrustsc.com
Clementia Pharmaceuticals Inc. (NASDAQ:CMTA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Clementia Pharmaceuticals Inc. (NASDAQ:CMTA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024